Targeted therapy and pharmacogenomic programsIQBAL, Syma; LENZ, Heinz Josef.Cancer. 2003, Vol 97, Num 8, pp 2076-2082, issn 0008-543X, 7 p., SUPConference Paper

Angiogenesis inhibitors in the treatment of colorectal cancerIQBAL, Syma; LENZ, Heinz-Josef.Seminars in oncology. 2004, Vol 31, Num 6, pp 10-16, issn 0093-7754, 7 p., SUP17Article

Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patientsRUBINSON, Douglas A; HOCHSTER, Howard S; ROSE, Jeffrey et al.Investigational new drugs. 2014, Vol 32, Num 1, pp 113-122, issn 0167-6997, 10 p.Article

Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiationSCHNEIDER, Sylke; PARK, David J; DONGYUN YANG et al.Pharmacogenetics and genomics (Print). 2006, Vol 16, Num 8, pp 555-563, issn 1744-6872, 9 p.Article

Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancerWU ZHANG; PRESS, Oliver A; LENZ, Heinz-Josef et al.Journal of clinical oncology. 2007, Vol 25, Num 24, pp 3726-3731, issn 0732-183X, 6 p.Article

FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor-expressing metastatic colorectal cancer patients treated with single-agent cetuximabWU ZHANG; GORDON, Michael; IQBAL, Syma et al.Journal of clinical oncology. 2007, Vol 25, Num 24, pp 3712-3718, issn 0732-183X, 7 p.Article

S0356: A Phase II Clinical and Prospective Molecular Trial With Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Before Surgery for Patients With Esophageal AdenocarcinomaLEICHMAN, Lawrence P; GOLDMAN, Bryan H; DANENBERG, Kathleen D et al.Journal of clinical oncology. 2011, Vol 29, Num 34, pp 4555-4560, issn 0732-183X, 6 p.Article

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancerRAMANATHAN, Ramesh K; BELANI, Chandra P; LURJE, Georg et al.Cancer chemotherapy and pharmacology. 2009, Vol 64, Num 4, pp 777-783, issn 0344-5704, 7 p.Article

Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly scheduleGARCIA, Agustin A; PUJARI, Mahesh; JEFFERS, Susan et al.Cancer chemotherapy and pharmacology. 2005, Vol 56, Num 1, pp 75-82, issn 0344-5704, 8 p.Article

A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumorsIQBAL, Syma; LENZ, Heinz-Josef; GANDARA, David R et al.Cancer chemotherapy and pharmacology. 2013, Vol 72, Num 1, pp 85-91, issn 0344-5704, 7 p.Article

A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202IQBAL, Syma; RANKIN, Cathryn; LENZ, Heinz-Josef et al.Cancer chemotherapy and pharmacology. 2011, Vol 68, Num 6, pp 1595-1602, issn 0344-5704, 8 p.Article

Molecular determinants of cetuximab efficacyVALLBÖHMER, Daniel; WU ZHANG; GROSHEN, Susan et al.Journal of clinical oncology. 2005, Vol 23, Num 15, pp 3536-3544, issn 0732-183X, 9 p.Article

Integration of novel agents in the treatment of colorectal cancerIQBAL, Syma; LENZ, Heinz-Josef.Cancer chemotherapy and pharmacology. 2004, Vol 54, pp S32-S39, issn 0344-5704, SUP1Conference Paper

A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancerSTOEHLMACHER, Jan; GHADERI, Vanessa; IQBAL, Syma et al.Anticancer research. 2001, Vol 21, Num 4B, pp 3075-3079, issn 0250-7005Article